John R. Teerlink

Featured in: Favicon

wiley.com (+1) Favicon

nature.com Favicon

jamanetwork.com Favicon

oxfordjournals.org Favicon

thelancet.com Favicon

healio.com Favicon

onlinejacc.org Favicon

onlinejcf.com Favicon

eurheartj.oxfordjournals.org + 1 more

Articles

New and future heart failure drugs - Nature Cardiovascular Research

Dec 3, 2024 | nature.com | John R. Teerlink

AbstractIn the past decade, our understanding of heart failure pathophysiology has advanced significantly, resulting in the development of new medications such as angiotensin–neprilysin inhibitors, sodium–glucose cotransporter-2 inhibitors and oral soluble guanylate cyclase stimulators.
Time from admission to randomization and the effect of empagliflozin in acute heart failure: A post‐hoc analysis from EMPULSE

Jul 9, 2024 | onlinelibrary.wiley.com | Joao Ferreira |Jonathan Blatchford |John R. Teerlink |Mikhail Kosiborod

Supporting Information Filename Description ejhf369-sup-0001-FigureS1.docxWord 2007 document , 365.2 KB Appendix S1. Supporting Information. References 1, , , , , , et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: A multinational randomized trial. Nat Med 2022; 28: 568–574. https://doi.org/10.1038/s41591-021-01659-1 2, , , , , , et al. Impact of empagliflozin on decongestion in acute heart failure: The EMPULSE trial.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →